These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8943140)

  • 1. Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis.
    Roth CR; Glaze LE; Goding GS; David WS
    J Voice; 1996 Dec; 10(4):362-7. PubMed ID: 8943140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
    Whurr R; Lorch M; Fontana H; Brookes G; Lees A; Marsden CD
    J Neurol Neurosurg Psychiatry; 1993 May; 56(5):526-30. PubMed ID: 8505645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
    Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
    J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia.
    Ludlow CL; Naunton RF; Sedory SE; Schulz GM; Hallett M
    Neurology; 1988 Aug; 38(8):1220-5. PubMed ID: 3399071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of laryngological abnormalities in patients with amyotrophic lateral sclerosis.
    Tomik J; Tomik B; Partyka D; Skladzien J; Szczudlik A
    J Laryngol Otol; 2007 Nov; 121(11):1064-9. PubMed ID: 17319997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of using botulism toxin in the treatment of spasmodic dysphonia].
    Larrosa F; Idígora A; Aguilar F; Riera L; Martí MJ; Valls J
    Acta Otorrinolaringol Esp; 2002 Jan; 53(1):27-31. PubMed ID: 11998515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia.
    Maloney AP; Morrison MD
    J Otolaryngol; 1994 Jun; 23(3):160-4. PubMed ID: 8064952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
    Holzer SE; Ludlow CL
    Laryngoscope; 1996 Jan; 106(1 Pt 1):86-92. PubMed ID: 8544635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of spasmodic dysphonia with botulinum toxin].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
    Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
    Sulica L; Blitzer A; Brin MF; Stewart CF
    Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy.
    Murry T; Woodson GE
    J Voice; 1995 Dec; 9(4):460-5. PubMed ID: 8574315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin in the treatment of recalcitrant mutational dysphonia.
    Woodson GE; Murry T
    J Voice; 1994 Dec; 8(4):347-51. PubMed ID: 7858670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
    Adler CH; Bansberg SF; Krein-Jones K; Hentz JG
    Mov Disord; 2004 Sep; 19(9):1075-9. PubMed ID: 15372600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
    Adams SG; Hunt EJ; Charles DA; Lang AE
    J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does botulinum toxin alter laryngeal secretions and mucociliary transport?
    Fisher KV; Giddens CL; Gray SD
    J Voice; 1998 Sep; 12(3):389-98. PubMed ID: 9763190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia.
    Wong DL; Adams SG; Irish JC; Durkin LC; Hunt EJ; Charlton MP
    J Otolaryngol; 1995 Aug; 24(4):209-16. PubMed ID: 8551532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
    Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S
    J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
    Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
    Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin for the treatment of spasmodic dysphonia.
    Gibbs SR; Blitzer A
    Otolaryngol Clin North Am; 2000 Aug; 33(4):879-94. PubMed ID: 10918666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia.
    Lundy DS; Lu FL; Casiano RR; Xue JW
    J Voice; 1998 Dec; 12(4):460-6. PubMed ID: 9988033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.